New data has revealed that tens of thousands of rheumatoid arthritis (RA) sufferers who cannot take the current mainstay of treatment, methotrexate (MTX), are almost four times as likely to achieve disease remission from RoActemra (tocilizumab) compared to patients taking the most widely prescribed anti TNF, Humira (adalimumab).
Reported especially with your perspective and understanding of arthritis in mind. What matters most to those of us with arthritis.
CreakyJoints' Seth Ginsberg's open letter to Mayor Bloomberg after he announced a ban on sodas and sugary drinks in New York City.
Moderate to severe chronic pain management clinical trials in pediatric patients
CreakyJoints is putting together a special report.
First biologic available in both subcutaneous (SC) and intravenous (IV) formulations for the treatment of rheumatoid arthritis. Subcutaneous ORENCIA demonstrated similar efficacy (non-inferior for American College of Rheumatology [ACR] 20 responses at 6 months) to the intravenous formulation and a consistent safety profile at 6 months. The overall frequency of injection site reactions was 2.6% (19/736) and 2.5% (18/721) for the ORENCIA SC group and the ORENCIA IV group (SC placebo), respectively. The overall immunogenicity frequency to ORENCIA was 1.1% (8/725) and 2.3% (16/710) for the subcutaneous and intravenous groups, respectively. High patient retention rates (94%) were seen with the subcutaneous and intravenous formulations at 6 months.
America's leaders CAN effectively control government spending and contain healthcare costs WITHOUT putting the Medicare program and its patients and seniors on the chopping block.
This is the third of a three-part special report by CreakyJoints about the dangers of oxycodone.
New research shows significantly higher osteoarthritis (OA) incidence rates in military populations than among comparable age groups in the general population.
A Study of the Effects of Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA).